Gland Pharma Reports Nearly 97% Rise in Q4 Net Profit on Revenue Growth
1 hour agoBusiness
30LENS
3 SourcesBhilwara, India
TBNthebalanced.news

Gland Pharma Reports Nearly 97% Rise in Q4 Net Profit on Revenue Growth

Gland Pharma reported a 96.6% year-on-year increase in consolidated net profit to approximately Rs 367 crore for Q4 FY26, driven by a 22.3% rise in revenue to around Rs 1,743 crore. Profit before tax rose 75%, supported by growth in key markets including the US and Europe. For FY26, net profit increased 47% to Rs 1,027 crore on 14.5% higher sales. The company launched multiple products in the US and continued investment in complex injectables, despite a one-time exceptional charge related to new labour codes.

Political Bias
0%100%0%
Sentiment
75%
AI analysis of 3 sources · Published under editorial oversight by The Balanced News
Analysed 15 May 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 3 sources
● Left 0%● Center 100%● Right 0%

The articles primarily present financial and operational data without political framing. Coverage focuses on corporate performance, regulatory filings, and market expansion, reflecting a business-centric perspective. There is no evident political bias, as the sources emphasize factual reporting of company results and strategic developments without partisan commentary.

Sentiment — Positive (75/100)

The overall tone across the articles is positive, highlighting significant profit and revenue growth alongside product launches and regulatory approvals. While noting an exceptional charge related to labour code implementation, the coverage maintains an optimistic outlook on the company’s financial health and future prospects, reflecting a generally favorable sentiment.

How 3 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
freepressjournalGland Pharma Q4 Profit Surges 97 To 367 Crore, Revenue Rises 22CenterPositive
businessstandardGland Pharma Q4 PAT jumps 97 YoY to Rs 367 croreCenterPositive
businessstandardGland Pharma consolidated net profit rises 96.57 in the March 2026 quarterCenterPositive

Coverage timeline

businessstandard broke this story on 15 May, 12:41 pm. Other outlets followed.

  1. 1
    businessstandard15 May, 12:41 pm
    Gland Pharma consolidated net profit rises 96.57 in the March 2026 quarter
  2. 2
    businessstandard15 May, 12:41 pm
    Gland Pharma Q4 PAT jumps 97 YoY to Rs 367 crore
  3. 3
    freepressjournal15 May, 01:01 pm
    Gland Pharma Q4 Profit Surges 97 To 367 Crore, Revenue Rises 22

Lens Score breakdown

30/100
Public interest0/100
Coverage gap90%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Gland Pharma LimitedGland Pharma

Story context

Category
Business
Location
Bhilwara, India
Sources analysed
3
Last analysed
15 May 2026
Key entities
CroreIndian rupeeRevenueNet incomeGlandEarnings before interest, taxes, depreciation, and amortizationIndiaAccountingBrimonidineDalbavancinChennai Super KingsInjection (medicine)